Table 1.

FDA approved anticancer therapeutics.

Generic name	Trade name	Molecular target	Approved indication
Regorafenib	Stivarga	VEGFR2; TIE2	Liver cancer
Brigatinib	Alunbrig	ALK; EGFR	Lung cancer
Ibrutinib	Imbruvica	BTK	Lymphoma
Midostaurin	Rydapt	FLT3; KIT	Leukemia
Olaratumab	Lartruvo	PDGFRα	Soft-tissue sarcoma
Ribociclib	Kisqali	CDK4/6	Breast cancer
Dabrafenib	Tafinlar	BRAF	Lung cancer
Trametinib	Mekinist	MEK1/2	Lung cancer
Neratinib	Nerlynx	HER2/EGFR	Breast cancer
Niraparib	Zejula	PARP1/2	Ovarian cancer
Rucaparib	Rubraca	PARP1/2	Ovarian cancer
Atezolizumab	Tecentriq	PD-L1	Lung cancer
Avelumab	Bavencio	PD-L1	Bladder cancer, skin cancer
Durvalumab	Imfinzi	PD-L1	Bladder cancer
Nivolumab	Opdivo	PD-1	Head and neck cancer, bladder cancer
Pembrolizumab	Keytruda	PD-1	Head and neck cancer, bladder cancer, lymphoma